<--- Back to Details
First PageDocument Content
Piperazines / Breakthrough therapy / Nintedanib / Boehringer Ingelheim / Kasumigaseki / Adverse effect / Ministry of Health /  Labour /  and Welfare / Package insert
Date: 2016-08-04 23:26:02
Piperazines
Breakthrough therapy
Nintedanib
Boehringer Ingelheim
Kasumigaseki
Adverse effect
Ministry of Health
Labour
and Welfare
Package insert

Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

Add to Reading List

Source URL: www.pmda.go.jp

Download Document from Source Website

File Size: 74,51 KB

Share Document on Facebook

Similar Documents

Findings that shed new light on the possible pathogenesis of a disease or an adverse effect Chronic carbon monoxide poisoning resulting in bilateral cataracts and a cystic globus pallidus lesion Shivani Kasbekar,1 Jose A

Findings that shed new light on the possible pathogenesis of a disease or an adverse effect Chronic carbon monoxide poisoning resulting in bilateral cataracts and a cystic globus pallidus lesion Shivani Kasbekar,1 Jose A

DocID: 1uw60 - View Document

Press contact: Eric Young, , (orcell)  Experiment suggests that pop-up ads can have an adverse effect on consumers’ perceptions of the content. CHICAGO, April 18, 2017

Press contact: Eric Young, , (orcell) Experiment suggests that pop-up ads can have an adverse effect on consumers’ perceptions of the content. CHICAGO, April 18, 2017

DocID: 1tKSS - View Document

orlistat and pcoc orlistat 60 mg studies persistence analysis sibutramine orlistat, clinical studies orlistat, orlistat and gall stones does orlistat work, health problems and orlistat orlistat and appetite. orlistat pre

orlistat and pcoc orlistat 60 mg studies persistence analysis sibutramine orlistat, clinical studies orlistat, orlistat and gall stones does orlistat work, health problems and orlistat orlistat and appetite. orlistat pre

DocID: 1rrCO - View Document

NON-INSURED HEALTH BENEFITS First Nations and Inuit Health Branch DRUG BENEFIT LIST 2016

NON-INSURED HEALTH BENEFITS First Nations and Inuit Health Branch DRUG BENEFIT LIST 2016

DocID: 1rp6w - View Document

Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion Idursulfase ▼This medicine is subject to additional monitoring. This will allow quick identification of new safety inform

Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion Idursulfase ▼This medicine is subject to additional monitoring. This will allow quick identification of new safety inform

DocID: 1reFq - View Document